Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126277 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-06-17 | 2022-07-19 | 162910 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-09-24 | 2021-11-19 | 146154 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2024-09-27 | 2024-12-20 | 238844 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2017-08-24 | 2017-09-22 | 20281 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Actual shortage | 2025-04-10 | 2025-05-01 | 254838 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2018-03-13 | 2018-07-03 | 42717 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-06-04 | 2020-07-28 | 116533 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-04-13 | 2020-05-22 | 111901 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-05-08 | 2020-05-22 | 114285 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2018-01-18 | 2018-02-12 | 36432 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-08-06 | 2020-11-28 | 121891 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2023-09-07 | 2023-09-15 | 203819 |
| APO-DEFERASIROX (TYPE J) | 360MG | TABLET | Resolved | 2021-12-03 | 2021-12-20 | 150432 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE TABLETS | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |